secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2026-08-20T19:27:04+00:00
Accession:  0001437749-26-028628
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma's MDC subsidiary names Michael Richtmyer Head of Operations
--------------------------------------------------------------------------------

- Michael G. Richtmyer appointed Head of Operations at Manhattan Drug Company, effective August 3, 2026.
- Richtmyer brings 35+ years in pharma/nutraceutical ops; was President of Tishcon Corp., overseeing 2 contract manufacturing sites.
- He previously worked at Integrated BioPharma from 1991 to 1999 and returns with expanded leadership experience.
- Will lead manufacturing, supply chain, quality systems, and scalable growth across MDC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926028628/0001437749-26-028628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926028628/inbp20260820_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer